ES2275304T3 - Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas. - Google Patents

Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas. Download PDF

Info

Publication number
ES2275304T3
ES2275304T3 ES98915305T ES98915305T ES2275304T3 ES 2275304 T3 ES2275304 T3 ES 2275304T3 ES 98915305 T ES98915305 T ES 98915305T ES 98915305 T ES98915305 T ES 98915305T ES 2275304 T3 ES2275304 T3 ES 2275304T3
Authority
ES
Spain
Prior art keywords
delta3
polypeptide
protein
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98915305T
Other languages
English (en)
Spanish (es)
Inventor
Sean A. Mccarthy
David P. Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2275304(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/872,855 external-priority patent/US6121045A/en
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2275304T3 publication Critical patent/ES2275304T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES98915305T 1997-04-04 1998-04-06 Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas. Expired - Lifetime ES2275304T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83263397A 1997-04-04 1997-04-04
US832633 1997-04-04
US08/872,855 US6121045A (en) 1997-04-04 1997-06-11 Human Delta3 nucleic acid molecules
US872855 1997-06-11

Publications (1)

Publication Number Publication Date
ES2275304T3 true ES2275304T3 (es) 2007-06-01

Family

ID=27125549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98915305T Expired - Lifetime ES2275304T3 (es) 1997-04-04 1998-04-06 Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas.

Country Status (8)

Country Link
EP (1) EP0972041B2 (fr)
JP (1) JP2001521382A (fr)
AT (1) ATE342358T1 (fr)
AU (1) AU6952498A (fr)
CA (1) CA2285020A1 (fr)
DE (1) DE69836131T3 (fr)
ES (1) ES2275304T3 (fr)
WO (1) WO1998045434A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861261B9 (fr) 1995-06-28 2010-02-24 Imperial Cancer Research Technology Limited Sequences nucleotidiques et proteiques de genes delta de vertebres et procedes fondes sur ces dernieres
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
CA2288218C (fr) * 1997-05-14 2013-03-12 Asahi Kasei Kogyo Kabushiki Kaisha Nouvel inhibiteur de differentiation
JP2002523018A (ja) * 1998-07-27 2002-07-30 アムジエン・インコーポレーテツド デルタ関連ポリペプチド
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
WO2001012664A2 (fr) * 1999-08-19 2001-02-22 Chiron Corporation Ligands recepteurs du gene notch, et utilisations associees
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
GB9927331D0 (en) 1999-11-18 2000-01-12 Fluorescience Ltd Assay for measuring enzyme activity in vivo
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
EP1438402A2 (fr) * 2001-08-22 2004-07-21 Galapagos Genomics N.V. Modulateurs de l'homeostasie osseuse identifies dans un criblage a haut rendement
JP2003245084A (ja) 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2006344359B2 (en) 2005-10-31 2013-08-15 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008060705A2 (fr) 2006-06-06 2008-05-22 Genentech, Inc. Anticorps anti-dll4 et leurs procédés d'utilisation
BRPI0717431A2 (pt) 2006-09-29 2013-11-12 Oncomed Pharm Inc Composições e métodos de diagnóstico e tratamento do câncer
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
EP2106439B1 (fr) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas
WO2010037041A2 (fr) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
US9403904B2 (en) 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
ES2895226T3 (es) 2009-10-16 2022-02-18 Mereo Biopharma 5 Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
DK2530091T3 (en) 2010-01-29 2018-05-28 Chugai Pharmaceutical Co Ltd ANTI-DLL3 ANTIBODY
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
PL3485903T3 (pl) 2011-09-23 2023-06-12 Mereo Biopharma 5, Inc. Środki wiążące VEGF/DLL4 i ich zastosowania
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN107530419B (zh) 2014-10-31 2021-05-18 昂考梅德药品有限公司 治疗疾病的组合疗法
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
EP0861261B9 (fr) 1995-06-28 2010-02-24 Imperial Cancer Research Technology Limited Sequences nucleotidiques et proteiques de genes delta de vertebres et procedes fondes sur ces dernieres
US6337387B1 (en) * 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide

Also Published As

Publication number Publication date
JP2001521382A (ja) 2001-11-06
EP0972041B1 (fr) 2006-10-11
DE69836131T3 (de) 2017-06-14
EP0972041B2 (fr) 2017-01-18
AU6952498A (en) 1998-10-30
DE69836131T2 (de) 2007-08-30
DE69836131D1 (de) 2006-11-23
EP0972041A1 (fr) 2000-01-19
ATE342358T1 (de) 2006-11-15
CA2285020A1 (fr) 1998-10-15
WO1998045434A1 (fr) 1998-10-15

Similar Documents

Publication Publication Date Title
ES2275304T3 (es) Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas.
US6121045A (en) Human Delta3 nucleic acid molecules
US7838294B2 (en) Inhibitors of the JNK signal transduction pathway and methods of use
US6524799B1 (en) DNA encoding sparc-related proteins
ES2284214T3 (es) Nuevas moleculas de la familia de las proteinas tango-77 y usos de las mismas.
ES2284502T3 (es) 22025, una nueva nucleotido ciclico fosfodiesterasa humana.
US20030180784A1 (en) Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US5800998A (en) Assays for diagnosing type II diabetes in a subject
US5885776A (en) Glaucoma compositions and therapeutic and diagnositic uses therefor
US6399760B1 (en) RP compositions and therapeutic and diagnostic uses therefor
KR20070085342A (ko) ｖＷＦＡ 및/또는 ＡＮＴ_ＩＧ 도메인 보유 단백질
US6221841B1 (en) General receptors for phosphoinositides and uses related thereto
CA2262696A1 (fr) Bcl-x gamma, un nouveau isoforme de bcl-x et ses utilisations
WO1998005777A9 (fr) BCL-xη, UNE NOUVELLE ISOFORME DE BCL-x, ET UTILISATIONS ASSOCIEES
JP2002510508A (ja) 緑内障の治療剤および診断剤
CA2271235A1 (fr) Proteine associee au glaucome, acide nucleique correspondant et leurs utilisations diagnostiques et therapeutiques
US20030105002A1 (en) RGS compositions and therapeutic and diagnostic uses therefor
JP2004509602A (ja) ポリペプチド、およびそれをコードする核酸
CA2250124A1 (fr) Nouvelles molecules appelees "trio" et leurs utilisations
US6008014A (en) Method of making lipid metabolic pathway compositions
US6271026B1 (en) Glaucoma compositions
CA2430082A1 (fr) Nouvelles proteines humaines specifiques de la retine c7orf9, c12orf7, mpp4 et f379
WO1998009979A9 (fr) Compositions relatives a la voie metabolique lipidique et utilisations therapeutiques et diagnostiques de telles compositions
WO2003005034A2 (fr) Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene
US20060019248A1 (en) Mutant sh-3 binding protein compositions and methods